real peptides FAQ

Persistent or increased IL-6 at week 8 or 12 suggests ongoing inflammatory stimulus unrelated to senescent cells. Possible sources include chronic infection (Lyme, EBV, CMV), autoimmune flare, gut dysbiosis, or hidden malignancy. FOXO4-DRI targets senescent cells specifically; if IL-6 rises, the inflammation is not senescence-driven. Discontinue the protocol and investigate alternative inflammatory sources before considering senolytic re-challenge.

Stop the protocol immediately and repeat labs within 48 hours. Creatinine increase above 0.2 mg/dL suggests impaired renal clearance or acute kidney injury. FOXO4-DRI is renally eliminated, and rising creatinine means the peptide is accumulating rather than clearing. If repeat labs confirm the increase, discontinue use and refer to nephrology. Do not resume until creatinine returns to baseline and eGFR stabilizes.

Reduce your dose by 50% or shift administration timing earlier in the evening. DSIP's half-life is short (30–45 minutes), but its downstream effects on endogenous opioid release can persist for 8–10 hours in sensitive individuals. Morning grogginess typically indicates that slow-wave sleep extension is bleeding into your normal wake time—essentially, your brain is still in deep sleep mode when your alarm goes off. Intranasal dosing at 15–25 nanomoles, administered 60–90 minutes before bed rather than 30 minutes, allows the peptide's peak effect to occur earlier in the sleep cycle without extending SWS into the morning hours.

Extend your protocol to 12–16 weeks at 2.5–5mg once or twice weekly, and don't expect visible improvement before week 6. Chronic injuries involve fibrotic tissue, reduced vascularity, and senescent cell populations that respond slowly to regenerative peptides. TB-4 works by stimulating MMPs to break down disorganized scar tissue while promoting organized collagen deposition. But remodeling fibrosis takes months. If you stop at week 6 because you "don't feel anything," you've abandoned the protocol before structural changes become apparent.

Legitimate clinical trials are registered on ClinicalTrials.gov and conducted under Institutional Review Board (IRB) oversight with informed consent, safety monitoring, and defined endpoints. As of 2026, no active trials are evaluating Ipamorelin specifically for hair regrowth. If such trials emerge, participation would require medical screening, baseline hair density measurements (using standardised phototrichogram analysis), and regular follow-up to assess both efficacy and adverse events like insulin resistance or joint swelling associated with GH secretagogue use.

No. Dermal papilla cell proliferation in a petri dish and hair cycle acceleration in mice are mechanistically interesting but don't predict human clinical outcomes. Dozens of compounds show hair growth activity in rodent models yet fail in human trials due to species differences, insufficient tissue penetration, or adverse effects at therapeutic doses. The gap between "biologically active" and "clinically effective" is where most investigational therapies stall. And hair restoration research has one of the highest failure rates in translational dermatology.

Administer 5–10mg twice weekly for three weeks instead of two, then transition to weekly maintenance dosing. You've missed the peak inflammatory window, but TB-4 still promotes angiogenesis and collagen organization during the proliferative phase (days 4–21 post-injury). Research suggests delayed initiation reduces total healing acceleration by roughly 25%, but benefits remain significant. Particularly for reducing scar tissue density and improving tissue quality. Don't skip the protocol entirely because you missed the first 48 hours.

Document the pharmacokinetic rationale for route selection in your protocol amendment and submit for institutional review. If the research question depends on stable plasma concentrations rather than peak levels, SubQ administration serves the study design better even if IM was the original plan. Include bioavailability data (87% SubQ vs 62–91% IM) and contamination risk differentials (0.4% vs 1.8%) in your justification. Most review boards approve route changes when the scientific basis is clear.

Discard it. Cloudiness indicates peptide aggregation or precipitation, both of which render FOXO4-DRI biologically inactive. Aggregated peptide cannot cross cell membranes or bind to intracellular FOXO4 protein. This typically results from reconstituting too quickly, using water that wasn't at proper temperature (2–8°C), or attempting to dissolve a peptide that was partially degraded before reconstitution. The fix for future vials: ensure the lyophilised peptide and bacteriostatic water are both at 2–8°C before mixing, inject water slowly down the vial wall rather than directly onto the peptide, and allow 60–90 seconds of gentle swirling rather than shaking.

Rising hs-CRP during P21 administration suggests an acute inflammatory response unrelated to the peptide itself. Infection, injury, or autoimmune flare. P21 doesn't cause systemic inflammation; it modulates central nervous system neuroplasticity. If hs-CRP rises above 3.0 mg/L during the protocol, pause P21 administration and investigate the source of inflammation. Resume only after hs-CRP normalizes. Continuing the peptide during acute inflammation wastes the compound and delays resolution of the underlying condition.

Reduce your dose to 10mg for one week, then titrate back up to 12.5mg. Water retention from MK 677 is driven by increased aldosterone secretion in response to elevated GH. It's transient in 85% of users and resolves by week three as the renin-angiotensin-aldosterone system recalibrates. If retention persists beyond four weeks, consider splitting your dose (half in morning, half at night) to smooth the GH curve rather than taking the full dose at once.

Assess for cofactor deficiencies and underlying conditions impairing recycling. Low plasma glutathione despite supplementation usually indicates one of three problems: inadequate vitamin C or selenium (preventing GSSG-to-GSH recycling), chronic inflammation consuming glutathione faster than supplementation replaces it, or genetic polymorphisms in GCLC or GSS genes reducing synthesis capacity. Request a comprehensive oxidative stress panel including reduced glutathione, oxidized glutathione (GSSG), GSH:GSSG ratio, and markers like 8-OHdG and F2-isoprostanes. If the ratio is skewed toward GSSG, the recycling pathway is the bottleneck. Increase vitamin C to 2,000mg daily and ensure selenium intake is adequate.

Acute inflammatory marker elevation 4–6 weeks post-cycle indicates either injection-site reaction (rare but possible with non-sterile reconstitution technique), concurrent illness or injury during the post-cycle period, or. In approximately 5% of cases. A paradoxical pro-inflammatory response to telomerase upregulation in subjects with existing autoimmune conditions. Rule out confounding factors first: recheck labs 2 weeks later when acute illness has resolved, verify injection technique used proper bacteriostatic water and sterile syringes, and review concurrent supplement or medication use. Persistent elevation warrants discontinuation and medical consultation.

Inject at least 3–4 hours post-meal instead. Injecting within 2 hours of eating means circulating insulin suppresses hormone-sensitive lipase, blocking the triglyceride breakdown that LIPO-C is designed to facilitate. The lipotropic compounds will still be absorbed, but methionine gets routed into muscle protein synthesis and homocysteine metabolism rather than hepatic lipid export. If your schedule only allows post-meal injection, choose a low-carbohydrate meal (under 20g carbs) to minimise insulin response. Protein and fat have minimal impact on insulin compared to carbohydrates.

This reaction indicates excessive nicotinic acid conversion, typically from NR rather than NMN. Switch to a time-release NR formulation or reduce your dose to 100mg and titrate upward slowly over 4 weeks. Flushing is caused by GPR109A receptor activation in the skin. It's harmless but uncomfortable. If it persists, replace NR with NMN entirely and increase the NMN dose to 500–600mg to compensate. Some individuals lack sufficient NRK1/NRK2 enzyme activity to convert NR efficiently without side effects, in which case NMN is the better-tolerated precursor. One trick: taking aspirin 30 minutes before NR can block prostaglandin-mediated flushing, though this is a workaround rather than a solution.

Monitor the injectable peptides, not the Snap-8. Run baseline IGF-1, fasting glucose, HbA1c, and lipid panels before starting the systemic compound, then follow up at 8-week intervals. The topical Snap-8 won't interact with these markers or alter the results. It operates in a separate pharmacological space entirely. Track visual wrinkle reduction for Snap-8 efficacy; track lab values for the GH secretagogue.

Switch to an NAD+ precursor. NMN or NR. At 250–500mg daily, taken in the morning. Oral NAD+ has near-zero bioavailability, so months of use won't produce mitochondrial effects. Precursors cross cell membranes intact and are converted to NAD+ inside cells where it's needed. You should notice shifts in energy or recovery within 10–14 days if the switch is made correctly.

Contact the supplier immediately and request a temperature strip reading or replacement. Lyophilised P21 can tolerate brief ambient exposure (24–48 hours at temperatures below 25°C), but prolonged heat exposure during summer shipping often exceeds that window. If no temperature monitoring was included and the package felt warm on arrival, the conservative approach is to request a replacement rather than risk using a compromised vial. At Real Peptides, temperature-monitored cold chain shipping is standard. If the strip indicates a breach, we replace the vial at no cost.

Check for elevated protease activity in your tissue type. Wound tissue, aged dermis, and inflamed samples express high levels of matrix metalloproteinases (MMP-2, MMP-9, MMP-13) that cleave AHK-Cu before it reaches target cells. Run a control experiment: pre-treat one sample set with EDTA (1–2 mM) to inhibit MMPs, apply AHK-Cu, then compare collagen synthesis or SOD activity against untreated samples. If the inhibitor-treated group shows response and the untreated group doesn't, your failure mode is extracellular degradation. Not peptide inactivity.

Request the COA before purchase. If they can't provide it within 24 hours, assume it doesn't exist. Legitimate suppliers with third-party verification publish COAs directly on product pages because the data supports their quality claims. Suppliers who require email requests or only provide COAs 'upon request' are usually hiding gaps in testing coverage or relying on in-house analysis with no external oversight. We publish Janoshik COAs because we have nothing to hide.